Obalon Announces Receipt of Delisting Notification Letters from Nasdaq
The Company has 45 days, or until July 1, 2019, to submit a plan to regain compliance with the minimum stockholders' equity requirement. If Nasdaq accepts the plan, it may grant the Company an extension of up to 180 days from the date of the notice to regain compliance. In the event that Nasdaq does not accept the Company’s compliance plan, the Company’s common stock will be delisted, although the Company will have the opportunity to appeal the decision. Alternatively, the Company may apply to transfer to the
To regain compliance with the minimum bid price requirement, the Company’s common stock must have a closing bid price of at least
To the extent that statements contained in this press release are not descriptions of historical facts regarding
Chief Financial Officer
Office: +1 760 607 5103
Source: Obalon Therapeutics, Inc.